What is Ascendis Pharma?
Ascendis Pharma A/S is a global biopharmaceutical entity dedicated to pioneering novel therapies for unmet medical needs. The company's core innovation lies in its proprietary TransCon® technology platform, designed to create treatments that offer improved safety, efficacy, tolerability, and convenience. Ascendis Pharma's development focus encompasses rare endocrinology diseases and other critical health conditions, with a robust pipeline that includes both commercialized products and candidates progressing through clinical trials. The company's operational footprint spans internationally, with key facilities and offices located in Copenhagen, Denmark, as well as across Europe and the United States.
How much funding has Ascendis Pharma raised?
Ascendis Pharma has raised a total of $108M across 1 funding round:
Stock Offering
$108M
Stock Issuance/Offering (2015): $108M, investors not publicly disclosed
What's next for Ascendis Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Ascendis Pharma is in a robust growth phase, likely focused on scaling its commercial operations and accelerating the development of its promising TransCon® technology-based therapies. This capital infusion is expected to fuel further clinical trial advancements, potential market expansions, and the ongoing refinement of its innovative treatment modalities. The company's strategic positioning suggests a continued emphasis on addressing significant unmet medical needs within its chosen therapeutic areas.
See full Ascendis Pharma company page
